JPH0335009A - 新規ポリスチレンアニオン交換樹脂 - Google Patents

新規ポリスチレンアニオン交換樹脂

Info

Publication number: JPH0335009A
Authority: JP; Japan
Prior art keywords: polymer; formula; structural formula; represented; alkyl group
Prior art date: 1989-06-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2156624A

Other languages

English (en)

Japanese (ja)

Inventor

Albert Andrzej Jaxa-Chamiec

アルバート・アンドレッジ・ヤクサ―シャミエク

Deirdre Mary Bernadette Hickey

デイルドレ・メアリー・バーナデット・ヒッキイ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GSK PLC

Original Assignee

GlaxoSmithKline PLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-14

Filing date

1990-06-14

Publication date

1991-02-15

1990-06-14 Application filed by GlaxoSmithKline PLC filed Critical GlaxoSmithKline PLC

1991-02-15 Publication of JPH0335009A publication Critical patent/JPH0335009A/ja

Status Pending legal-status Critical Current

Links

239000004793 Polystyrene Substances 0.000 title abstract description 34
229920002223 polystyrene Polymers 0.000 title abstract description 34
239000003957 anion exchange resin Substances 0.000 title abstract description 3
229920000642 polymer Polymers 0.000 claims abstract description 85
150000001875 compounds Chemical class 0.000 claims abstract description 12
150000001412 amines Chemical class 0.000 claims abstract description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
229910052757 nitrogen Inorganic materials 0.000 claims description 11
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
229920006395 saturated elastomer Polymers 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 4
125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
239000000126 substance Substances 0.000 claims 3
238000004519 manufacturing process Methods 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
229920005989 resin Polymers 0.000 abstract description 12
239000011347 resin Substances 0.000 abstract description 12
125000000217 alkyl group Chemical group 0.000 abstract description 9
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 abstract description 4
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 abstract description 4
239000003795 chemical substances by application Substances 0.000 abstract description 4
150000002500 ions Chemical class 0.000 abstract description 2
229920001577 copolymer Polymers 0.000 abstract 1
150000003242 quaternary ammonium salts Chemical class 0.000 abstract 1
150000003440 styrenes Chemical class 0.000 abstract 1
150000003512 tertiary amines Chemical class 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 61
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
239000000203 mixture Substances 0.000 description 21
239000003613 bile acid Substances 0.000 description 17
239000011324 bead Substances 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
238000001914 filtration Methods 0.000 description 11
108010011222 cyclo(Arg-Pro) Proteins 0.000 description 10
-1 halogen ions Chemical class 0.000 description 10
229920005990 polystyrene resin Polymers 0.000 description 10
150000003839 salts Chemical class 0.000 description 9
239000000243 solution Substances 0.000 description 9
150000003841 chloride salts Chemical class 0.000 description 8
238000000034 method Methods 0.000 description 8
238000010992 reflux Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 6
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
201000001320 Atherosclerosis Diseases 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000000926 separation method Methods 0.000 description 4
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000035150 Hypercholesterolemia Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
230000002440 hepatic effect Effects 0.000 description 3
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000010626 work up procedure Methods 0.000 description 3
RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
229920001268 Cholestyramine Polymers 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000003833 bile salt Substances 0.000 description 2
229940093761 bile salts Drugs 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
239000003999 initiator Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
BZZXQZOBAUXLHZ-UHFFFAOYSA-N (c-methylsulfanylcarbonimidoyl)azanium;sulfate Chemical compound CSC(N)=N.CSC(N)=N.OS(O)(=O)=O BZZXQZOBAUXLHZ-UHFFFAOYSA-N 0.000 description 1
OAZFTIPKNPTDIO-UHFFFAOYSA-N 2-(6-bromohexyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCCCBr)C(=O)C2=C1 OAZFTIPKNPTDIO-UHFFFAOYSA-N 0.000 description 1
LIPUTCBPMRHRRK-UHFFFAOYSA-N 2-[11-(dimethylamino)undecyl]isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCCCCCCCCN(C)C)C(=O)C2=C1 LIPUTCBPMRHRRK-UHFFFAOYSA-N 0.000 description 1
IWTYTFSSTWXZFU-UHFFFAOYSA-N 3-chloroprop-1-enylbenzene Chemical compound ClCC=CC1=CC=CC=C1 IWTYTFSSTWXZFU-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
206010058842 Cerebrovascular insufficiency Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
102000000853 LDL receptors Human genes 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
101100184046 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mid1 gene Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
244000240602 cacao Species 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
238000007265 chloromethylation reaction Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
208000028831 congenital heart disease Diseases 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
230000010235 enterohepatic circulation Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000015203 fruit juice Nutrition 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229940097042 glucuronate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
230000005802 health problem Effects 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
BJEPYKJPYRNKOW-UWTATZPHSA-M malate ion Chemical compound [O-]C(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-M 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
238000003918 potentiometric titration Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/44—Preparation of metal salts or ammonium salts

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Polymers & Plastics (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

JP2156624A 1989-06-14 1990-06-14 新規ポリスチレンアニオン交換樹脂 Pending JPH0335009A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8913699.8		1989-06-14
GB898913699A GB8913699D0 (en)	1989-06-14	1989-06-14	Compounds

Publications (1)

Publication Number	Publication Date
JPH0335009A true JPH0335009A (ja)	1991-02-15

Family

ID=10658442

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2156624A Pending JPH0335009A (ja)	1989-06-14	1990-06-14	新規ポリスチレンアニオン交換樹脂

Country Status (4)

Country	Link
US (1)	US5110875A (fr)
EP (1)	EP0403198A3 (fr)
JP (1)	JPH0335009A (fr)
GB (1)	GB8913699D0 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992001477A1 (fr) *	1990-07-26	1992-02-06	G.D. Searle & Co.	Systeme d'apport de medicaments comprenant un materiau polymere
US5556619A (en) *	1992-08-20	1996-09-17	The Du Pont Merck Pharmaceutical Company	Crosslinked polymeric ammonium salts
ZA95390B (en) *	1994-01-18	1996-07-18	Du Pont	Crosslinked polymeric ammonium salts
FR2742157B1 (fr) *	1995-12-11	1998-01-16	Elf Aquitaine	Nouveau mode de preparation de resines a fonction guanidine et obtention de nouvelles resines a fonction guanidine
US6114466A (en) *	1998-02-06	2000-09-05	Renal Tech International Llc	Material for purification of physiological liquids of organism
US6861473B2 (en) *	2003-02-28	2005-03-01	Baxter International Inc.	Macromolecular ketoaldehydes
US8277649B2 (en) *	2009-12-14	2012-10-02	General Electric Company	Membranes and associated methods for purification of antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE580490A (fr) *	1958-07-15	1960-01-08	Merck & Co Inc	Compositions et procédés pour abaisser la teneur en cholestérol du sang
NL7017227A (fr) *	1969-12-27	1971-06-29
GB1428835A (en) *	1972-05-30	1976-03-17	Maruzen Oil Co Ltd	Cationic polyelecrrolytes
US3989088A (en) *	1975-12-29	1976-11-02	Ipco Hospital Supply Corporation (Whaledent International Division)	Casting machine and improved control circuit for operation
FR2352547A1 (fr) *	1976-05-25	1977-12-23	Viridis Ets	Nouvelle resine anionique a action hypocholesterolemiante, son procede de preparation et compositions therapeutiques la contenant
JPS54100489A (en) *	1978-01-26	1979-08-08	Asahi Chem Ind Co Ltd	New basic crosslinked copolymer and its preparation
IT1097396B (it) *	1978-07-24	1985-08-31	Texcontor Ets	Resine scambiatrici di ioni del tipo anionico con proprieta' ipocolesterolemizzanti
US4273898A (en) *	1979-09-06	1981-06-16	Suntech, Inc.	Block copolymer of polyetheramide and random copolymer of polyamide and polyetheramide
US4373031A (en) *	1980-09-25	1983-02-08	Ionics, Incorporated	Synthesis of anion exchange polymers employing ditertiary amines
WO1983001002A1 (fr) *	1981-09-15	1983-03-31	Dynapol Shareholders Liquidati	Polymeres contenant un groupe d'ammonium quaternaire et possedant une activite antimicrobienne
US4532128A (en) *	1981-09-15	1985-07-30	Dynapol	Quaternary ammonium group-containing polymers having antimicrobial activity
CH655507B (fr) *	1983-01-12	1986-04-30
JPS6234159A (ja) *	1985-08-08	1987-02-14	Fuji Photo Film Co Ltd	写真要素

1989
- 1989-06-14 GB GB898913699A patent/GB8913699D0/en active Pending
1990
- 1990-06-11 EP EP19900306330 patent/EP0403198A3/fr not_active Withdrawn
- 1990-06-12 US US07/536,837 patent/US5110875A/en not_active Expired - Fee Related
- 1990-06-14 JP JP2156624A patent/JPH0335009A/ja active Pending

Also Published As

Publication number	Publication date
EP0403198A2 (fr)	1990-12-19
GB8913699D0 (en)	1989-08-02
EP0403198A3 (fr)	1992-02-12
US5110875A (en)	1992-05-05

Publication	Publication Date	Title
JP3931217B2 (ja)	2007-06-13	患者から胆汁酸塩を除去する方法およびそのためのアルキル化組成物
KR0179675B1 (ko)	1999-03-20	콜레스테롤저하제
JP4420143B2 (ja)	2010-02-24	高コレステロール血症を治療するためのポリアリルアミンポリマー
EP1416942B1 (fr)	2007-12-12	Aminopolymeres pour traiter la goutte et pour fixer l'acide urique
EP0373852B1 (fr)	1994-10-26	Composés
US7229613B2 (en)	2007-06-12	Method for lowering serum glucose
SK31395A3 (en)	1995-08-09	Crosslinked polymeric ammonium salts
JPS5879022A (ja)	1983-05-12	第四級窒素原子を含有する新規な金属架橋高分子化合物、その製法及び該高分子化合物を有効成分とする高脂血症治療剤
EP0375350B1 (fr)	1994-04-20	Polyméres rèticulès de vinylpiridinium
WO2002085380A1 (fr)	2002-10-31	Methode pour traiter la goutte et reduire les taux d'acide urique serique
EP0432995B1 (fr)	1995-02-22	Polymères réticulés de pyridinio-acrylates
JPH0335009A (ja)	1991-02-15	新規ポリスチレンアニオン交換樹脂
US5273740A (en)	1993-12-28	Polystyrene anion exchange polymers
JPH0335010A (ja)	1991-02-15	新規ポリスチレンアニオン交換樹脂
JPH11500130A (ja)	1999-01-06	抗ウイルス性トリアザ化合物
EP0322209B1 (fr)	1993-02-10	Compositions
JPH0331308A (ja)	1991-02-12	新規ポリスチレンアニオン交換樹脂
JPH0335005A (ja)	1991-02-15	新規ポリスチレンアニオン交換樹脂
CA2012564A1 (fr)	1990-09-23	Polyamines a chaines laterales portant des groupements fonctionnels pouvant servir d'agents hypolipidemiques hydrosolubles
US5230885A (en)	1993-07-27	Polystyrene anion exchange polymer pharmaceutical composition
CN116018146A (zh)	2023-04-25	用于治疗高尿酸血症的聚合物、组合物和方法
EP0385686A2 (fr)	1990-09-05	Composés
AU608114B2 (en)	1991-03-21	Compounds